Za Pharmacy

Drugs, Supplies and Delivery

Alogliptin/Glimepiride Tablets

Alogliptin/glimepiride is a fixed-dose combination oral antidiabetic medication used to manage type 2 diabetes mellitus. This article examines its pharmacology, clinical applications, and safety profile, drawing on the British National Formulary (BNF)Lippincott Textbook of Pharmacology, and Lange Basic & Clinical Pharmacology.

Alogliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor, alogliptin enhances glucose-dependent insulin secretion by prolonging the activity of incretin hormones (GLP-1 and GIP). These hormones suppress glucagon release, slow gastric emptying, and reduce hepatic glucose production (Lippincott). DPP-4 inhibition increases active incretin levels by 2-3 fold, improving both fasting and postprandial hyperglycemia (BNF).

Glimepiride: A sulfonylurea, glimepiride stimulates insulin secretion from pancreatic β-cells by binding to ATP-sensitive potassium (K⁺ATP) channels, causing cell depolarization and calcium influx. It also enhances peripheral insulin sensitivity (Lange).

Combined Effect: The dual action addresses insulin deficiency (glimepiride) and improves incretin-mediated glucose regulation (alogliptin), offering complementary glycemic control (BNF).

  • Primary Indication: Management of type 2 diabetes mellitus in adults inadequately controlled by monotherapy (e.g., metformin) or as an adjunct to diet/exercise when dual therapy is warranted.
  • Adjunctive Therapy: May be combined with other agents (e.g., metformin, insulin) under specialist guidance (BNF).
  • Available Strengths: Alogliptin (12.5 mg or 25 mg) combined with glimepiride (1 mg, 2 mg, or 4 mg). Common formulations include 12.5/1, 12.5/2, 25/1, and 25/2 mg (BNF).
  • Standard Dose: Once daily with the first meal of the day.
    • Alogliptin: Adjust for renal impairment (e.g., 12.5 mg daily if eGFR <60 mL/min; avoid if eGFR <30 mL/min).
    • Glimepiride: Initiate at 1–2 mg/day, titrated gradually to avoid hypoglycemia (max 8 mg/day).
  • Elderly/Hepatic Impairment: Use lower glimepiride doses due to prolonged hypoglycemia risk (Lange).
  • Alogliptin: Nasopharyngitis, headache, upper respiratory infections.
  • Glimepiride: Hypoglycemia (dose-dependent), weight gain, dizziness.

Serious:

  • Glimepiride: Severe hypoglycemia (especially in elderly/renal impairment), hemolytic anemia (rare), hypersensitivity.
  • Alogliptin: Acute pancreatitis (rare), angioedema, joint pain (BNF).
  • Contraindications:
    • Type 1 diabetes, diabetic ketoacidosis, severe renal/hepatic impairment.
    • Hypersensitivity to sulfonylureas or DPP-4 inhibitors.
    • Blood glucose (to detect hypoglycemia), renal function, HbA1c, and liver enzymes.
    • Signs of pancreatitis (e.g., severe abdominal pain, vomiting).

Category C (glimepiride); avoid due to hypoglycemia risk in neonates.

  • Glimepiride:
    • CYP2C9 Inhibitors (e.g., fluconazole, amiodarone): Increase hypoglycemia risk.
    • Beta-blockers: Mask hypoglycemia symptoms.
    • Alcohol: Disulfiram-like reaction (rare) or potentiated hypoglycemia.
  • Alogliptin:
    • CYP3A4 Inducers (e.g., rifampicin): May reduce efficacy.
  • General:
    • Hypoglycemia risk heightened with insulin, other sulfonylureas, or GLP-1 agonists. Avoid concurrent use with pioglitazone due to additive edema risk (Lippincott).
  • Generic: Alogliptin/glimepiride.

Brand Examples: Not widely marketed; available as generics in some regions (e.g., India).

Book Now

Order Your Medications with Ease

We provide fast and secure prescription reservations—place your order now and pick it up from the nearest pharmacy!